Bajaj Healthcare Limited has announced the successful completion of its postal ballot voting process, with all seven special resolutions receiving approval from shareholders. The remote e-voting concluded on February 19, 2026 at 5.00 pm (IST), with results submitted to stock exchanges in compliance with SEBI regulations.

Postal Ballot Overview

The postal ballot was conducted entirely through electronic voting via NSDL's platform, spanning from January 20, 2026 at 9.00 am (IST) to February 19, 2026 at 5.00 pm (IST). The company had 38426 shareholders eligible to vote as of the record date of January 16, 2026.

Resolution Results

All seven special resolutions were passed with overwhelming shareholder support. The resolutions covered key board appointments and re-appointments of senior management positions.

New Independent Director Appointments

Three new independent directors were appointed to strengthen the board:

Management Re-appointments

Four key management personnel were re-appointed to their respective positions:

Voting Participation Analysis

The voting showed strong participation from promoter groups and institutional investors:

Promoter and Promoter Group:

• Shares held: 18695042
• Voting participation: 100.0000%
• Unanimous support for all resolutions

Public Institutions:

• Shares held: 1303474
• Voting participation: 46.0205%
• Strong support across all resolutions

Public Non-Institutions:

• Shares held: 11584736
• Voting participation: 0.1033%
• Mixed but generally supportive voting pattern

Regulatory Compliance

The postal ballot process was conducted in full compliance with Section 108 of the Companies Act, 2013 and SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Mr. Haresh Sanghvi, a practicing Company Secretary (FCS 2259), served as the scrutinizer and submitted his detailed report confirming the fairness and transparency of the e-voting process.

The voting results and scrutinizer's report have been made available on the company's website at https://www.bajajhealth.com/ and NSDL's website at www.evoting.nsdl.com , ensuring complete transparency for all stakeholders.

Bajaj Healthcare Limited announced strong Q3FY26 financial results with revenue from operations growing 31.3% year-on-year to ₹1,612.2 million, driven primarily by exceptional performance in API exports. The pharmaceutical manufacturer, specializing in APIs, intermediates and formulations, demonstrated robust operational momentum across key business segments for the quarter ended December 31, 2025.

Financial Performance Highlights

The company's financial metrics showed significant improvement across multiple parameters during Q3FY26:

EBITDA growth of 34.6% to ₹323.3 million outpaced revenue growth, with margins expanding to 19.8% from 19.2% in the corresponding quarter last year. Profit for the period surged 33.7% to ₹156.7 million, reflecting improved operational efficiency.

Segment-wise Revenue Performance

API exports emerged as the standout performer, driving overall revenue growth:

API exports more than doubled with growth of 109.8% to ₹486.8 million, demonstrating the company's expanding presence in international markets. Domestic API business maintained steady growth of 15.3% to ₹838.5 million, while formulations contributed ₹287.0 million with 6.8% growth.

Nine-Month Performance

For the nine months ended December 31, 2025, Bajaj Healthcare sustained strong momentum:

Nine-month revenue reached ₹4,579.7 million with 18.0% growth, while profit for the period increased 36.4% to ₹386.2 million, indicating sustained operational improvements throughout the fiscal year.

Key Business Developments

The company achieved several significant regulatory and product milestones during the quarter:

• Became the first Indian company to receive CDSCO approval for Phase III clinical trials and bioequivalence studies of Suvorexant Tablets
• Successfully launched Magnesium L-Threonate (Magtein) in India through collaboration with Threotech LLC
• Filed 9 Drug Master Files (DMFs) during the quarter, bringing cumulative DMF filings to 69
• Maintained ten cumulative CEP filings with eight approved and two under review

These developments strengthen the company's position in regulated markets and expand its CNS portfolio offerings.

Management Commentary

Managing Director Anil Jain highlighted the company's resilient performance amid global volatility, emphasizing the strong API export growth and expanding CDMO business. He noted the company's continued focus on CNS portfolio advancement with ongoing Phase III trials for Cenobamate and the recent Magtein launch, while maintaining emphasis on regulatory compliance and product registrations across key geographies for sustained growth in regulated markets.